Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
EVGN | US
0.18
7.50%
Healthcare
Biotechnology
30/06/2024
21/10/2024
2.58
2.38
2.78
2.23
Evogene Ltd. together with its subsidiaries operates as a computational biology company. It focuses on product discovery and development in life-science based industries including human health and agriculture through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture Human Health and Industrial Applications. The Agriculture segment develops seed traits ag-chemical products and ag-biological products to enhance plant performance. Its products focus on various crops such as corn soybean wheat rice and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology GI related disorders and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States Israel Brazil and internationally. The company has strategic collaborations and licensing agreements with agricultural companies such as BASF SE Corteva and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot Israel.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
118.9%1 month
118.9%3 months
100.4%6 months
81.8%-
-
3.74
0.26
0.02
-0.81
0.39
-
-19.67M
14.44M
14.44M
-
-667.07
-
39.80
-82.37
0.63
0.27
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.73
Range1M
1.18
Range3M
5.18
Rel. volume
2.45
Price X volume
264.99K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Apollomics Inc. Class A Ordinary Shares | APLM | Biotechnology | 0.1368 | 15.04M | 6.79% | n/a | 21.43% |
| Indaptus Therapeutics Inc. Common Stock | INDP | Biotechnology | 1.47 | 14.99M | -2.63% | n/a | 2.12% |
| Cingulate Inc. Common Stock | CING | Biotechnology | 4.92 | 14.98M | 7.19% | n/a | 10.72% |
| ImmunoPrecise Antibodies Ltd | IPA | Biotechnology | 0.5352 | 14.94M | -0.89% | n/a | 49.00% |
| Cara Therapeutics Inc | CARA | Biotechnology | 0.2656 | 14.57M | 0.19% | n/a | 406.66% |
| IMNN | IMNN | Biotechnology | 0.9925 | 14.29M | 0.71% | n/a | 37.13% |
| Evaxion Biotech A/S | EVAX | Biotechnology | 2.54 | 14.17M | -3.79% | n/a | 837.11% |
| Cyclacel Pharmaceuticals Inc | CYCCP | Biotechnology | 7.3 | 13.88M | 0.00% | n/a | 0.50% |
| Tenax Therapeutics Inc | TENX | Biotechnology | 4.05 | 13.81M | 2.53% | n/a | 3.14% |
| Aytu BioScience Inc | AYTU | Biotechnology | 2.23 | 13.71M | -2.62% | n/a | 54.59% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
| Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.81 | - | Cheaper |
| Ent. to Revenue | 0.39 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.74 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 100.44 | - | Riskier |
| Debt to Equity | 0.26 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 14.44M | - | Emerging |